Growth Engines
India has built a substantial scientific and industrial workforce across chemicals, pharmaceuticals and biotechnology. However, the next stage of growth will depend less on graduate numbers and more on practical skills, advanced manufacturing capabilities, research capacity and stronger industry-academia collaboration.
Oct 30, 2026
Sustainability
The EU's CBAM regulation does not automatically apply to every chemical product. Here is how Indian exporters can verify exact product scope, classify goods correctly, and respond to customer requests without confusing voluntary data with legal obligations.
Oct 18, 2026
Policy & Incentives
India has approved 3 Bulk Drug Parks and commissioned 38 PLI greenfield projects. We analyze official capacity data (56,800 MT/year) and provide a supplier-development process to distinguish policy announcements from real purchasing demand.
Oct 18, 2026
Regulations
The DGTR has recommended a 5-year continuation of anti-dumping duties on specific arylides from China. Here is a practical compliance checklist to verify customs notifications, confirm product scope, and avoid landed-cost surprises.
Oct 18, 2026
pharma
India relies on China for over 95% of certain critical APIs like 6-APA and Erythromycin. We break down official FY24-25 import data, the reality of domestic manufacturing capacity, and where suppliers can find viable alternatives.
Oct 18, 2026